News Pfizer offers $60m to settle prescriber kickback claims Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.
News Pfizer’s migraine push builds with Zavzpret nod Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.
News AbbVie files Qulipta for chronic migraine prevention AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face